Effects of switching from agalsidase−α to agalsidase−β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report-Reference-Cited by-同舟云学术

Effects of switching from agalsidase−α to agalsidase−β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report

Published:2023-12-22 Issue: Volume: Page:
ISSN:2192-4449
Container-title:CEN Case Reports
language:en
Short-container-title:CEN Case Rep

Author:

Shima Hisato^ORCID,Tsukimura Takahiro,Shiga Tomoko,Togawa Tadayasu,Sakuraba Hitoshi,Doi Toshio,Ikeda Yuka,Okamoto Takuya,Yoshikawa Yukari,Kimura Takehiko,Iwase Takashi,Inoue Tomoko,Tashiro Manabu,Okada Kazuyoshi,Minakuchi Jun

Funder

Dainippon Sumitomo Pharma

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://link.springer.com/content/pdf/10.1007/s13730-023-00843-1.pdf

Reference28 articles.

1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.

2. Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, et al. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem Biophys Res Commun. 2010;399:716–20.

3. Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120:57–61.

4. Schiffmann R, Waldek S, Benigni A, Auray-Blais C. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5:360–4.

5. Nakamura K, Mukai S, Takezawa Y, Natori Y, Miyazaki A, Ide Y, et al. Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of Fabry disease. Mol Genet Metab Rep. 2023;36:100983.